CanSino Biologics Inc. (HKG:6185)
28.40
-0.20 (-0.70%)
Apr 10, 2025, 4:08 PM HKT
CanSino Biologics Employees
CanSino Biologics had 1,494 employees as of December 31, 2023. The number of employees decreased by 797 or -34.79% compared to the previous year.
Employees
1,494
Change (1Y)
-797
Growth (1Y)
-34.79%
Revenue / Employee
602.84K HKD
Profits / Employee
-269.88K HKD
Market Cap
10.38B
Employees Chart
Related Stocks
Company Name | Employees |
---|---|
BeiGene | 11,000 |
Hansoh Pharmaceutical Group Company | 8,989 |
JD Health International | 3,564 |
WuXi Biologics | 12,575 |
Innovent Biologics | 5,659 |
Alibaba Health Information Technology | 1,435 |
Sino Biopharmaceutical | 24,379 |
Sichuan Kelun-Biotech Biopharmaceutical | 1,837 |
CanSino Biologics News
- 2 years ago - Riding Covid Vaccine Highs, CanSino Plans Swiss Listing - Seeking Alpha
- 2 years ago - World-First Inhaled COVID-19 Vaccine, Developed in Partnership Between Aerogen® and CanSinoBIO, First Public Booster Immunization in China. - Business Wire
- 2 years ago - China's CanSinoBIO H1 revenue drops on weaker COVID shot demand - Reuters
- 3 years ago - CanSinoBIO's COVID-19 Vaccine Convidecia™ Receives WHO Emergency Use Listing - PRNewsWire
- 3 years ago - CanSinoBIO Rebrands to Reflect Commitment to Life Sciences Research - PRNewsWire
- 3 years ago - CanSinoBIO's COVID-19 mRNA Vaccine Receives Approval of Clinical Trial Application in China - PRNewsWire
- 3 years ago - CanSinoBIO's Convidecia™ Approved as Heterologous Booster in Malaysia and Indonesia - PRNewsWire
- 3 years ago - Latest Study Shows Advantages of CanSinoBIO's Convidecia™ as Heterologous Booster against Omicron Variant - PRNewsWire